Live Breaking News & Updates on Benjamin Besse

Stay updated with breaking news from Benjamin besse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC

Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial. ....

United States , France General , Benjamin Besse , Institut Gustave Roussy , Christabel Wilson , Merck Sharp Dohme , Genzyme Corporation , Oncology Congress , Merck Co Inc , Gustave Roussy Cancer Center , Paris Saclay University , Eastern Europe , Western Europe , Taiho Oncology , Turning Point , Merck Sharp , Blue Bell , Phase 3 Pearls Keynote 091 Trial , Adjuvant Treatment With Pembrolizumab , Disease Free Survival , Patients With Resected Early Stage Nsclc ,

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. ....

Soult Ukpyolsi , South Korea , United States , France General , Republic Of Korea , Eli Lilly , Perioperative Pembrolizumab , Daiichi Sankyo , Benjamin Besse , Medscape Web , Institut Curie , Roche Genentech , Byoung Chul Cho , Zosia Piotrowska , Gustave Roussy , Jarushka Naidoo , Nicolas Girard , Jonathand Spicer , Boehringer Ingelheim , Merck Sharp Dohme , Mcgill University , Genzyme Corporation , Research To Practice , Vyera Pharmaceuticals , Takeda Pharmaceuticals , Janssen Pharmaceuticals ,

OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine. ....

France General , Benjamin Besse , Institute Gustave Roussy , Ose2101 , Cancer Vaccine , Atalante 1 Trial , Hlaa 02 ,

'We Finally Made It': Amivantamab Comes of Age in NSCLC

Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings. ....

United States , South Korea , Soult Ukpyolsi , France General , Bristol Myers Squibb , Byoung Chul Cho , Antonio Passaro , Zofia Piotrowska , Institut Curie , Daiichi Sankyo , Nicolas Girard , Silke Gillessen , Svizzera Italiana , Eli Lilly , Benjamin Besse , Janssen Pharmaceuticals , Yonsei Cancer Center , Curie Montsouris Thorax Institute , European Society For Medical Oncology , Department Of Medical Oncology , European Institute Of Oncology , Gustave Roussy Institute , Hospital Cancer Center , Genzyme Corporation , Hoffmann La Roche , Saclay University ,

New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses ....

France General , Amivantamab Rybrevant , Gustave Roussy , Benjamin Besse , Ppeuropean Society For Medical Oncology , Eastern Cooperative Oncology Group , Medical Oncology , New England Journal , New Standard , Managing Editor , Medpage Today , England Journal , Englj Med ,